Table 2. SIRs for subsequent cancers by period of follow-up – seminomas.

	Time since diagnosis (years)
	0–9				10–19				20+
			95% CI				95% CI				95% CI
Site	No.	SIR	L	U	No.	SIR	L	U	No.	SIR	L	U
Stomach	8	1.60	0.69	3.15	1	0.24	0.01	1.32	4	1.86	0.51	4.76
Colon	7	0.88	0.35	1.81	6	0.83	0.30	1.81	10	2.36	1.13	4.35
Rectum	5	1.13	0.37	2.65	4	1.03	0.28	2.64	5	2.38	0.77	5.56
Pancreas	3	0.96	0.20	2.82	8	2.91	1.26	5.73	8	5.48	2.37	10.80
Lung	9	0.42	0.19	0.80	16	0.86	0.49	1.40	13	1.37	0.73	2.34
Soft tissue	1	1.81	0.05	10.11	2	5.82	0.70	21.01	2	13.64	1.65	49.28
Prostate	9	0.75	0.34	1.43	14	1.02	0.56	1.72	17	1.68	0.98	2.68
Testis	24	6.69	4.28	9.95	4	3.96	1.08	10.14	1	6.25	0.16	34.82
Kidney	3	1.08	0.22	3.14	2	0.84	0.10	3.04	2	1.65	0.20	5.97
Bladder	6	0.95	0.35	2.07	3	0.53	0.11	1.56	13	4.28	2.28	7.31
NHL	8	1.53	0.66	3.01	5	1.36	0.44	3.17	2	1.18	0.14	4.27
Leukaemia	10	3.01	1.44	5.54	1	0.39	0.01	2.18	6	4.48	1.64	9.75
Othera	16	0.54	0.31	0.88	15	0.65	0.36	1.07	23	2.01	1.28	3.02
Totala	109	1.04	0.85	1.25	81	0.91	0.72	1.13	106	2.18	1.79	2.64

NHL=Non-Hodgkin's lymphoma; SIRs=standardised incidence ratios.

^aExcluding nonmelanoma skin cancer.